Prognosticheskoe znachenie lokal'nogo i sistemnogo lecheniya pri rake molochnoy zhelezy I stadii
- Authors: Kolyadina I.V.1,2, Poddubnaya I.V.1,2, Trofimova O.P.1,2, Komov D.V.3, Karseladze A.I.3, Ermilova V.D.3, Vishnevskaya Y.V.3, Frank G.A.1, Banov S.M.4
-
Affiliations:
- ГБОУ ДПО РМАПО Минздрава РФ, Москва
- ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
- ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН
- Клиника ГБОУ ДПО РМАПО Минздрава РФ, Москва
- Issue: Vol 15, No 3 (2013)
- Pages: 33-40
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26906
- ID: 26906
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Irina Vladimirovna Kolyadina
ГБОУ ДПО РМАПО Минздрава РФ, Москва; ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
Email: irinakolyadina@yandex.ru
канд. мед. наук, врач-онколог, ассистент каф. онкологии ГБОУ ДПО РМАПО
Irina Vladimirovna Poddubnaya
ГБОУ ДПО РМАПО Минздрава РФ, Москва; ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москвачл.-кор. РАМН, д-р мед. наук, проф., зав. каф. онкологии ГБОУ ДПО РМАПО
Oksana Petrovna Trofimova
ГБОУ ДПО РМАПО Минздрава РФ, Москва; ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москваканд. мед. наук, вед. науч. сотр. отд-ния радиационной онкологии ФГБУ РОНЦ им. Н.Н.Блохина РАМН, доц. каф. онкологии ГБОУ ДПО РМАПО
Dmitriy Vladimirovich Komov
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМНд-р мед. наук, проф., зав. хирургическим отд-нием диагностики опухолей ФГБУ РОНЦ им. Н.Н.Блохина РАМН
Apollon Irodionovich Karseladze
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМНд-р мед. наук, проф., зав. отд-нием патологической анатомии опухолей ФГБУ РОНЦ им. Н.Н.Блохина РАМН
Valeriya Dmitrievna Ermilova
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМНд-р мед. наук, проф., вед. науч. сотр. отд-ния патологической анатомии опухолей ФГБУ РОНЦ им. Н.Н.Блохина РАМН
Yana Vladimirovna Vishnevskaya
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМНканд. мед. наук, науч. сотр. отд-ния патологической анатомии опухолей ФГБУ РОНЦ им. Н.Н.Блохина РАМН
Georgiy Avraamovich Frank
ГБОУ ДПО РМАПО Минздрава РФ, Москвад-р мед. наук, проф., зав. каф. патологической анатомии ГБОУ ДПО РМАПО
Sergey Mikhaylovich Banov
Клиника ГБОУ ДПО РМАПО Минздрава РФ, Москваканд. мед. наук, врач-онколог Клиники ГБОУ ДПО РМАПО
References
- Hofmann D, Nitz U, Gluz O et al. WSG ADAPT – adjuvant dynamic marker - adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi - center, controlled, non - blinded, randomized, investigator initiated phase II/III trial. Trials 2013; 14 (1): 261.
- Ignatiadis M, Sotiriou C. Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol 2013; 10 (9): 494–506.
- Mihály Z, Gyõrffy B. HER2-positive breast cancer: available targeted agents and biomarkers of therapy response. Magy Onkol 2013; 57 (3): 147–56.
- Mohamed A, Krajewski K, Cakar B, Ma C.X. Targeted therapy for breast cancer. Am J Pathol 2013; 183 (4): 1096–112.
- Goldhirsch A. Personalized adjuvant therapies. Lessons from the past: The opening address by the St. Gallen 2013 award recipient. Breast 2013; 222: s3–7.
- Sestak I, Dowsett M, Zabaglo L et al. Factors predicting late recurrence for estrogen receptor - positive breast cancer. J Natl Cancer Inst 2013; 105 (19): 1504–11.
- Ismaili N, Elmajjaoui S, Tahri A et al. Trastuzumab in early breast cancer. Presse Med 2013; 42 (7–8): 1069–80.
- Harbeck N, Thomssen C, Gnant M. St. Gallen 2013: brief preliminary summary of the consensus discussion. Breast Care (Basel) 2013; 8 (2): 102–9.
- Petrelli F, Coinu A, Cabiddu M et al. Five or more years of adjuvant endocrine therapy in breast cancer: a meta - analysis of published randomised trials. Breast Cancer Res Treat 2013; 140 (2): 233–40.
- Coudert B, Asselain B, Campone M et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node - positive breast cancer: the 8-year follow - up results of the UNICANCER-PACS01 trial. Oncolog 2012; 17 (7): 900–9.
- Christinat A, Di Lascio S, Pagani O. Hormonal therapies in young breast cancer patients: when, what and for how long? J Thorac Dis 2013; 5 (Suppl. 1): s36–46.
- Barron T.I, Cahir C, Sharp L, Bennett K. A nested case - control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I–III breast cancer. Br J Cancer 2013; 109 (6): 1513–21.
- Hernandez-Aya L.F, Gonzalez-Angulo A.M. Adjuvant systemic therapies in breast cancer. Surg Clin North Am 2013; 93 (2): 473–91.
- De Laurentiis M, Cancello G, D’Agostino D et al. Taxane - based combinations as adjuvant chemotherapy of early breast cancer. A meta - analysis of randomized trials. J Clin Oncol 2008; 26: 44–53.
- Mackey J.R, Martin M, Pienkowski T et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node - positive breast cancer: 10-year follow - up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 2013; 14 (1): 72–80.
- Eiermann W, Pienkowski T, Crown J et al. Phase III study of doxorubicin/cyclophosphamide with concomitant vs sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node - positive breast cancer: BCIRG 005 trial. J Clin Oncol 2011; 29 (29): 3877–84.
- Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365 (14): 1273–83.
- Sgroi D.C, Sestak I, Cuzick J et al. Prediction of late distant recurrence in patients with oestrogen - receptor - positive breast cancer: a prospective comparison of the breast - cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the Trans ATAC study population. Lancet Oncol 2013; 14 (11): 1067–76.
- Metzger-Filho O, Sun Z, Viale G et al. Patterns of recurrence and outcome according to breast cancer subtypes in lymph node - negative disease: results from International Breast Cancer Study Group Trials VIII and IX. J Clin Oncol 2013; 31 (25): 3083–90.
- Wolfe E, Corsetti R, Bolton J.S et al. The evolution in management of patients with subcentimeter, node - negative, triple - negative breast cancer. Am J Surg 2013.
- Nothacker M, Duda V, Hahn M et al. Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue. A systematic review. BMC Cancer 2009; 9: 335.
- Wan Y, Gao X, Mehta S. Indirect costs associated with metastatic breast cancer. J Med Econ 2013; 16 (10): 1169–78.
- Keen J.D. Analysis of health benefits and cost - effectiveness of mammography for breast cancer. Ann Intern Med 2011; 155 (8): 566.